Annabel Samimy

ANNABEL SAMIMY is an Associate Director in the healthcare group of UBS
Warburg Equity Research. An analyst since 1999, Ms. Samimy specializes
in the large capitalization biotechnology sector, with special areas of
interest in monoclonal antibody technologies, cancer and autoimmune
disease. Previously at UBS Warburg, Ms. Samimy worked as an Associate in
the structured finance group. Ms. Samimy received her MA in
International Affairs with a focus on International Finance and Business
from Columbia University and a BA in International Relations from Tufts
University.